Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Thiogenesis Therapeutics, Corp.Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate UpdateThiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.Meeting...
- Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP)Beacon Therapeutics, a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced positive topline results for its registration-enabling VISTA trial evaluating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).
- ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment OptionHONG KONG, Sept 21, 2026 - Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”. Everest Medicines acquired the rights to develop, manufacture, and commercialize CARDAMYST(R) (etripamil), a treatment for acute PSVT episodes, in Greater China (including Mainland China, Hong Kong, Macao and Taiwan) in March 2026. CARDAMYST(R) (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST(R) is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. The drug was approved by the National Medical Products Administration (NMPA) of China in September 2026, for the conversion of acute symptomatic episodes of paroxysmal PSVT to sinus rhythm in adults. According to clinical data, treatment effects can be observed as early as five minutes after administration, with 64% of patients achieving conversion to sinus rhythm within 30 minutes and a median time to conversion of 17 minutes. CARDAMYST(R) was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. Positioned as an on-demand treatment that enables patients to take control of their heart rhythm, CARDAMYST(R) empowers patients with PSVT to better manage their condition and their lives. It has the potential to transform the treatment paradigm for acute PSVT episodes from passive emergency care in hospitals to proactive self-management by patients, helping to alleviate anxiety during episodes, reduce emergency department visits and disease burden, and further improve long-term disease management and quality of life. Research presented at ESC Congress 2026 shows that PSVT is a chronic condition that continues to impact patients’ quality of life, rather than simply an occasional acute emergency. Patients with PSVT experience a substantial burden between episodes, with negative impacts on anxiety, daily activities, sleep, and work. Therefore, beyond acute treatment and subsequent catheter ablation, ensuring timely and convenient treatment during an episode is also an important aspect of PSVT management. For patients experiencing recurrent PSVT episodes, further data from studies of CARDAMYST(R) provide additional clinical support. The NODE-302 study evaluated patients with recurrent PSVT episodes during long-term follow-up. Across a total of 188 episodes, the overall conversion rate within 30 minutes was 60.2%, with a median time to conversion of 15.5 minutes and a cumulative conversion rate of 75.1% within 60 minutes. The conversion rate showed a numerical upward trend across multiple episodes. A patient’s response to the first episode was predictive of the response to subsequent episodes, with no evidence of diminished response with repeated use. In a patient-reported outcomes (PRO) analysis from the NODE-303 study, CARDAMYST(R) not only converted heart rhythm but also helped alleviate feelings of a racing or pounding heart and ease anxiety, with patients reporting sustained reductions from baseline in anxiety and stress related to future PSVT episodes. CARDAMYST(R) addresses the critical unmet need for acute self-treatment during PSVT episodes. By reducing the sense of losing control, it shifts the treatment focus from mere disease control to enhancing the overall patient experience. In December 2025, CARDAMYST(R) was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting PSVT to sinus rhythm in adults. CARDAMYST(R) is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. An estimated 3 to 6 million people in China are living with PSVT. Research presented at ESC Congress 2026 further highlights the quality-of-life burden experienced by patients between episodes, while CARDAMYST(R) offers an out-of-hospital, self-administered treatment option for acute episodes. As Everest Medicines’ first approved innovative therapy in the cardiovascular disease field, CARDAMYST(R) complements the Company’s existing portfolio and has the potential to benefit more than 12 million patients in China, including those with PSVT and atrial fibrillation with AFib-RVR.
- ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment OptionHONG KONG, Sept 21, 2026 - Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”. Everest Medicines acquired the rights to develop, manufacture, and commercialize CARDAMYST(R) (etripamil), a treatment for acute PSVT episodes, in Greater China (including Mainland China, Hong Kong, Macao and Taiwan) in March 2026. CARDAMYST(R) (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST(R) is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. The drug was approved by the National Medical Products Administration (NMPA) of China in September 2026, for the conversion of acute symptomatic episodes of paroxysmal PSVT to sinus rhythm in adults. According to clinical data, treatment effects can be observed as early as five minutes after administration, with 64% of patients achieving conversion to sinus rhythm within 30 minutes and a median time to conversion of 17 minutes. CARDAMYST(R) was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. Positioned as an on-demand treatment that enables patients to take control of their heart rhythm, CARDAMYST(R) empowers patients with PSVT to better manage their condition and their lives. It has the potential to transform the treatment paradigm for acute PSVT episodes from passive emergency care in hospitals to proactive self-management by patients, helping to alleviate anxiety during episodes, reduce emergency department visits and disease burden, and further improve long-term disease management and quality of life. Research presented at ESC Congress 2026 shows that PSVT is a chronic condition that continues to impact patients’ quality of life, rather than simply an occasional acute emergency. Patients with PSVT experience a substantial burden between episodes, with negative impacts on anxiety, daily activities, sleep, and work. Therefore, beyond acute treatment and subsequent catheter ablation, ensuring timely and convenient treatment during an episode is also an important aspect of PSVT management. For patients experiencing recurrent PSVT episodes, further data from studies of CARDAMYST(R) provide additional clinical support. The NODE-302 study evaluated patients with recurrent PSVT episodes during long-term follow-up. Across a total of 188 episodes, the overall conversion rate within 30 minutes was 60.2%, with a median time to conversion of 15.5 minutes and a cumulative conversion rate of 75.1% within 60 minutes. The conversion rate showed a numerical upward trend across multiple episodes. A patient’s response to the first episode was predictive of the response to subsequent episodes, with no evidence of diminished response with repeated use. In a patient-reported outcomes (PRO) analysis from the NODE-303 study, CARDAMYST(R) not only converted heart rhythm but also helped alleviate feelings of a racing or pounding heart and ease anxiety, with patients reporting sustained reductions from baseline in anxiety and stress related to future PSVT episodes. CARDAMYST(R) addresses the critical unmet need for acute self-treatment during PSVT episodes. By reducing the sense of losing control, it shifts the treatment focus from mere disease control to enhancing the overall patient experience. In December 2025, CARDAMYST(R) was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting PSVT to sinus rhythm in adults. CARDAMYST(R) is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. An estimated 3 to 6 million people in China are living with PSVT. Research presented at ESC Congress 2026 further highlights the quality-of-life burden experienced by patients between episodes, while CARDAMYST(R) offers an out-of-hospital, self-administered treatment option for acute episodes. As Everest Medicines’ first approved innovative therapy in the cardiovascular disease field, CARDAMYST(R) complements the Company’s existing portfolio and has the potential to benefit more than 12 million patients in China, including those with PSVT and atrial fibrillation with AFib-RVR.
- AbbiskoAbbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective...
- Telix and ITM Join Forces to Create a Radiopharmaceutical PowerhouseTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.
- Antengene Corporation LimitedAntengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Specialised TherapeuticsSpecialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in AustraliaCompanies: IncyteIndependent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register...
- Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026
- Faruqi & Faruqi LLPSPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]New York, New...
- Faruqi & Faruqi LLPUNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...
- Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous UrticariaResults support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study